Integra LifeSciences Shares Surge On Q3 Beat
Integra LifeSciences Holdings Corp (NASDAQ:IART) reported Q3 FY22 sales of $385.19 million, -0.4% Y/Y on a reported basis, and +3.5% organic,…
Accuray Announces Japanese Ministry Of Health, Labor And Welfare Has Approved Reimbursement Of Cyberknife System
Accuray Incorporated (NASDAQ:ARAY) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved reimbursement for the CyberKnife® System for the treatment of trigeminal neuralgia (TN).
NexGel Highlights Positive Data From Proof-of-Concept Study For Its Diclofenac Hydrogel Pain Treatment
NexGel Inc (NASDAQ:NXGL) announced results from its proof-of-concept study for its diclofenac hydrogel patches. The patches are designed to treat pain…
GSK Transfers Cell Therapy Program Rights To Adaptimmune, Terminates Second Cell Therapy Pact In A Day
GSK plc (NYSE:GSK) will transfer its NY-ESO cell therapy program and the right to the PRAME cell therapy program to Adaptimmune Therapeutics…
GSK Walks Away From T-Cell Therapy Pact With Lyell Citing Strategic Actions
GSK plc (NYSE:GSK) has decided to terminate the License and Collaboration Agreement with Lyell Immunopharma Inc (NASDAQ:LYEL). The termination is effective on December…
Contract Research Organization Medpace Lifts FY22 Guidance, Highlights FY23 Outlook
Medpace Holdings Inc’s (NASDAQ:MEDP) Q3 revenue increased 29.8% Y/Y to $383.7 million, beating the consensus of $357.18 million, representing a…
Biogen Q3 Earnings Preview: Key Items For Investors To Watch
Biogen Inc (NASDAQ: BIIB) is scheduled to report its third-quarter earnings on Tuesday during the premarket session amid cautious hope for its neurodegenerative disease programs and an ongoing
Why Accelerate Diagnostics Shares Are Plummeting Today?
Accelerate Diagnostics Inc (NASDAQ:AXDX) said that according to recent discussions, the FDA has clarified that the company must obtain a 510(k)…
Alpine Immune Sciences Stops Davoceticept Trials In Cancer Indications After Second Patient Death
Alpine Immune Sciences Inc (NASDAQ:ALPN) has voluntarily terminated enrollment in both clinical studies involving davoceticept (ALPN-202), an investigational CD28 costimulator, and…